|Endo Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 1, 2012|
CHADDS FORD, Pa., April 17, 2012 /PRNewswire via COMTEX/ --Endo Pharmaceuticals Holdings (Nasdaq: ENDP) will announce its first quarter 2012 financial results on May 1, 2012 and will host a conference call and webcast at 8:30 a.m. ET that day to discuss these results.
David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, and Blaine Davis, senior vice president, corporate affairs will host the call.
Investors and other interested parties may call 866-510-0710 (domestic) or 617-597-5378 (international) and enter passcode 71552059. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from May 1 at 10:30 a.m. ET until 12:00 p.m. ET on May 15 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 17794666.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 p.m. ET on May 15. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.
Endo Pharmaceuticals Holdings Inc. (Endo) is a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through our operating companies: AMS, Endo Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. Learn more at www.endo.com
SOURCE Endo Pharmaceuticals Holdings Inc.